PubMed Health⌕ Search

Biomedical subjects

Mario De Santis

Publications and source records attributed to Mario De Santis.

9 recordsLinked to original sources
PubMed2002

[Locoregional treatment of hepatocellular carcinoma: comparison between percutaneous alcohol administration and intraarterial chemoembolization].

Between 1991 and 1998, 45 cirrhotic patients with hepatocellular carcinoma (1 or 2 lesions smaller than 5 cm) were treated either with percutaneous ethanol injection (26 patients) or with trans arterial chemoembolization (19 patients) in our Department. Percutaneous ethanol injection was performed on 37 nodules: mean diameter of 3.1 +/- 0.8 cm. Transarterial chemoembolization was performed on 27 nodules: mean diameter of 2.8 +/- 0.7 cm. Therapeutic success at first treatment was obtained in 81.5% of percutaneous ethanol injection treated lesions and in 60.0% of trans arterial chemoembolization treated lesions. Local recurrence after first treatment occurred in 7 of 22 percutaneous ethanol injection patients (31.8%) and 8 of 15 transarterial chemoembolization patients (53.3%). Distant hepatic recurrence after first treatment occurred in 16 of 26 (61.5%) alcolization treated patients and in 14 of 25 (56.0%) chemoembolization treated. Multivariate analysis selected therapeutic success and modality of treatment as the best predictor of better survival probability in all treated patients. Survival probability at 12/24/36/48 months was 96.1/80.8/61.6/42.3% in percutaneous ethanol injection group and 89.5/68.4/36.8/15.8% in transarterial chemoembolization group (p < 0.05 Log rank). Few data are available comparing the efficacy of percutaneous ethanol injection and transarterial chemoembolization in patients with hepatocellular carcinoma. Our data confirm that percutaneous ethanol injection is better than trans arterial chemoembolization in the treatment of patients with one or two lesions of hepatocellular carcinoma.

Carcinoma, Hepatocellular↗
PubMedDate not supplied

Biological factors and therapeutic modulation in brain tumor radiotherapy.

Diagnosticotherapeutic approaches aimed at the improvement of prognosis of the most aggressive brain tumors tend to include new tools of investigation. Functional imaging, biologic markers, radiosensitizers, the combination of different modalities of radiation therapy and chemotherapy are being experimented. These new approaches to the neoplastic metabolism require increased resources and a close follow-up during treatment to better define the biological target volume. More sophisticated and aggressive techniques as intensity modulated radiation therapy or brachycurietherapy can be suitably included in combined modality therapy.

Biological Factors↗
PubMedDate not supplied

Biological optimization of the dose in stereotactic radiotherapy of brain tumors.

The techniques of radiotherapy with a high dose gradient require several demanding choices but represent a major innovation in the radiation therapy of brain tumors. To optimize the expected outcomes in terms of effectiveness and efficacy some recent acquisitions of biological parameters of integration of the linear-quadratic model are illustrated, aimed at the progressive understanding of the role of histology, dose fractionation, timing, toxicity and combined modality therapy.

Brain Neoplasms↗
PubMedDate not supplied

Impact of dose and volume on subcutaneous fibrosis.

The multifactorial genesis of radiation-induced fibrosis makes a general outline of the occurence of this late toxicity fairly unpredictable. Scientific knowledge about dose fractionation, irradiated volume, total time, conformation procedures including IMRT can help provide better treatments. Chemical and physical therapies aimed at the removal of fibrosis are still limited or under study. The system of monitoring late toxicity used by the authors is presented.

Comorbidity↗